Academy of Physicians
in Clinical Research

Academy of Physicians
in Clinical Research

News from SCRIP

APCR Members can get a free trial to SCRIP and a discount on a SCRIP subscription by contacting John Lezcano from SCRIP directly at the information below. 

John Lezcano
Corporate Account Manager

Pharma intelligence | informa
T: (212) 652-2678
M: (631) 807-4971

Deal Watch: Allergan Keeps After Hair Loss With Exicure Deal

Thu, 11/14/2019 - 12:09pm

Allergan has tried to go after alopecia in the past; Exicure brings a new spherical nucleic acid (SNA) technology. In other recent...

      Related Stories 

No Alarm At Almirall Despite Stake Sale

Thu, 11/14/2019 - 7:14am

Shares in the Spanish dermatology specialist have slipped as the majority shareholder sold a 6.3% stake. However, sales of its...

      Related Stories 

HES Flare: GSK's Nucala Edges Forward

Thu, 11/14/2019 - 6:48am

GlaxoSmithKline’s interleukin-5 inhibitor, Nucala (mepolizumab), is the first treatment shown to reduce the hypereosinophilic syndrome flare-ups in a 100-patient pivotal...

      Related Stories 

European Biotechs Enter the IPO Big League

Thu, 11/14/2019 - 3:55am

2019 has seen European biotech companies making waves in the US IPO space. Genmab’s listing was a blockbuster, but many...

      Related Stories 

Executives On The Move: Santhera Pharmaceuticals Announces Its Next CEO And Checkmate And Imago Bring Aboard Business Leaders

Thu, 11/14/2019 - 1:07am

Santhera Pharmaceuticals, developer of treatments for neuromuscular and pulmonary conditions, announces its next CEO, and cancer immunotherapy firm Checkmate Pharmaceuticals...

      Related Stories 

Merck Acquires Novel Neurodegenerative Disease Target With Calporta Buy

Wed, 11/13/2019 - 4:51pm

The deal worth up to $576m gives Merck what Calporta founding investor Avalon believes is the most advanced program targeting...

      Related Stories 

Novartis, Pfizer Advance Their NASH Ambitions Separately, As Partners

Wed, 11/13/2019 - 3:49pm

Novartis thinks tropifexor may prove to be best-in-class FXR agonist, while Pfizer notes the complementary activity of its ACC and...

      Related Stories 

Aurobindo Says Nothing ‘Extraneous’ Holding Up FTC Nod For Sandoz Deal

Wed, 11/13/2019 - 2:57pm

Aurobindo believes it has “substantially addressed” all requirements for an FTC go-ahead for its acquisition of Sandoz’s US dermatology and generic...

      Related Stories 

‘Watch China’ As Its Pharma Butterfly Flaps Its Wings

Wed, 11/13/2019 - 7:53am

More affordable drug prices worldwide could result from China’s ongoing reforms in the life sciences sector, the FT Global Pharmaceutical...

      Related Stories 

J&J Targets Tremfya Growth In PsA

Wed, 11/13/2019 - 7:37am

The healthcare giant is looking for a second approval for its IL-23 blocker and tells Scrip the results from the...

      Related Stories 

Staying Diversified, Bayer Sees Opportunities In Digital Innovation

Wed, 11/13/2019 - 4:16am

Despite its Monsanto woes, Bayer is sticking with its diversified portfolio, and is branching out into patient-facing digital health services.

      Related Stories 

Korean Biotech Sentiment Still Shaky But IPO Recovery Seen By Year-End

Tue, 11/12/2019 - 4:44pm

After a lackluster year so far for South Korean biotech IPOs amid disappointing clinical trial news, investor interest is beginning...

      Related Stories 

Japan Cancer Center Looks To Leverage Expertise As It Builds Pharma Ties

Tue, 11/12/2019 - 3:04pm

Japan's largest cancer center is looking to build on its tissue sample and genomic resources to further build its reputation...

      Related Stories 

VBI Looking To Market More Potent, Less Expensive Hepatitis B Vaccine

Tue, 11/12/2019 - 2:42pm

Sci-B-Vac was shown more effective at fewer doses than Engerix-B in a Phase III study. VBI Vaccines sees its hepatitis...

      Related Stories 

Roche's pRED Leaders On Its Next Generation Of Drugs

Tue, 11/12/2019 - 11:18am

"We're not resting on our laurels," pRED head William Pao said in an early R&D overview. The company's R&D leaders...

      Related Stories 

Cirius’ Mixed Phase IIb Results In NASH Don’t Quell Its Enthusiasm For Phase III

Tue, 11/12/2019 - 10:48am

Privately held biotech plans to move insulin sensitizer into Phase III with ambitious goals of obtaining accelerated approval based on...

      Related Stories 

Five Trials To Look Out For At The AHA Meeting

Tue, 11/12/2019 - 8:16am

Philadelphia is due to host the American Heart Association (AHA) meeting for the first time from 16-18 November, with the...

      Related Stories 

Reata's Bardoxolone Promises Renal Benefits In Alport Syndrome

Tue, 11/12/2019 - 7:25am

Reata is moving ahead with commercial plans as its potential first-in-class Nrf2 activator, bardoxolone methyl, meets primary and secondary endpoints...

      Related Stories